This synergistic interplay between ICIs and BRAF inhibitors has yielded impressive outcomes, exemplified by the combination of dabrafenib (a BRAF inhibitor), trametinib (a MEK inhibitor), and spartalizumab (an anti-PD-1 mAb), which demonstrated a remarkable 100% response rate and reduced relapse compared to BRAF-MEK inhibitor monotherapy in melanoma patients103-105. This evidence concerns the gene MAP2K7 and melanoma.